Neuroendocrine Carcinoma Clinical Trials in Seattle, Washington
6 recruitingSeattle, Washington
Showing 1–6 of 6 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2Phase 3
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled249 locationsNCT05058651
Recruiting
Phase 1
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Locally Advanced Merkel Cell CarcinomaSmall Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine Cancer+8 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 1Phase 2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled6 locationsNCT07006727
Recruiting
Phase 1Phase 2
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Small Cell Lung CancerNeuroendocrine CarcinomasSolid Tumor Show to Express DLL3
IDEAYA Biosciences208 enrolled39 locationsNCT07174583